Clinical Trials Logo

Salt-sensitive Hypertension clinical trials

View clinical trials related to Salt-sensitive Hypertension.

Filter by:
  • None
  • Page 1

NCT ID: NCT03775720 Not yet recruiting - Clinical trials for Salt-sensitive Hypertension

Disclosure of Genetic Risk for Salt Sensitivity

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

The global burden of cardiovascular disease (CVD) has decreased over the past 10 years. Nevertheless, the disease still kills one in three people. Hypertension is one of the leading causes of cardiovascular disease, with salt in the diet being a main contributor. Depending on an individual's DNA, participants may or may not be salt sensitive. Genotyping individuals for variants in a salt sensitivity gene (SLC4A5) may identify salt sensitive individuals which may benefit from a personalised dietary advice to reduce salt intake. Adherence to such advice can then be assessed which may aid in prevention of hypertension and CVD.

NCT ID: NCT01681576 Completed - Clinical trials for Salt-sensitive Hypertension

Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

Start date: August 2012
Phase: Phase 2
Study type: Interventional

This study will evaluate the effect of LCZ696 and valsartan on natriuresis, diuresis, and blood pressure in salt-sensitive Asian hypertensive patients.

NCT ID: NCT01324245 Completed - Clinical trials for Salt-sensitive Hypertension

Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet

Salt
Start date: November 2002
Phase: N/A
Study type: Interventional

The kidney plays a crucial role in maintaining salt balance by two opposing physiological mechanisms: the renal dopaminergic system which enhances salt excretion and the renin-angiotensin system (RAS) which causes salt retention. Salt-sensitive hypertension occurs when this balance is altered or abnormal. We hypothesized that this balance is influenced by salt intake: therefore dietary salt affects the natriuretic response to the renal dopaminergic agonist Fenoldopam, and the Angiotensin Converting Enzyme inhibitor, Enalapril. In this trial we study normal salt balance mechanisms in salt resistant adults with normal blood pressure.